Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Toolkit
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Physical Function Scores Help Predict Outcomes in Multiple Myeloma Treatment
July 2025
A new study finds that how patients feel and function before starting treatment can help predict how well they’ll respond to multiple myeloma therapies.
Read more
20 Jun 2025
High Readmission Rates Persist for Patients with Sickle Cell in Hospitals
A large-scale US study reveals that 34% of sickle cell disease patients are readmitted within 30 days of hospital discharge, nearly triple the rate of non-SCD patients.
19 Jun 2025
EHA 2025: Early Detection of Residual Disease Predicts Survival in Multiple Myeloma
In a major study presented at EHA, Noella Collado-Gisbert demonstrated that residual disease kinetics are a strong predictor of survival in multiple myeloma.
19 Jun 2025
EHA 2025: Ellagic Acid Shown to Protect Against Iron-Induced Liver Injury
Recognised with an EHA Young Abstract award, Hangjie Fu’s study reveals that ellagic acid significantly mitigates liver injury caused by iron overload.
18 Jun 2025
EHA 2025: CONCEPT Trial Shows Isatuximab Benefits High-Risk Myeloma
The Phase II CONCEPT trial has demonstrated that an isatuximab-based combination therapy achieves unprecedented rates of minimal residual disease negativity in patients with high-risk newly diagnosed multiple myeloma.
17 Jun 2025
EHA 2025: Circulating Tumour Cells Offer Prognostic Insight in Multiple Myeloma
A large European analysis confirms circulating tumour cells (CTCs) as an independent prognostic biomarker in newly diagnosed multiple myeloma.
7 Jun 2025
One-Third of Patients with Myeloma May Achieve Long-Term Survival
A new analysis of early total therapy clinical trials has revealed that up to one-third of patients with newly diagnosed multiple myeloma may achieve long-term survival.
6 Jun 2025
Lower Transfusion Thresholds May Be Safe for Children Post-Transplant
A new UK clinical trial has found that children undergoing stem cell transplants may safely receive fewer blood transfusions.
3 Jun 2025
Genomic Study Offers Breakthrough in Predicting Multiple Myeloma Progression
Loading posts...
« Previous
1
2
3
4
…
37
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View